



Profiles of Endoglin and Vascular Endothelial Growth Factor Based on Staging and Histological Grading of Colorectal Cancer, and Its Relationship with Bevacizumab Therapy Cancer
Rahmawati Minhajat

Hematology and Medical Oncology Division of Internal Medicine Department, Medical Faculty Hasanuddin University, Makassar, Indonesia.



ABSTRACT: This study evaluated the profile of CD105 (Endoglin) and VEGF protein based on staging and histopathological grading of Colorectal Cancer, and evaluated its relationship with bevacizumab therapy. A total of 88 cases of colorectal adenocarcinoma were included in this study.

The levels of VEGF and CD105 were evaluated with ELISA. There was a significant difference in CD105 protein level ($p=0.002$) between metastases and non-metastases subjects, where CD105 level is higher in metastatic colorectal adenocarcinoma (4.59ng/ml). There was no significant difference of VEGF protein level based on the presence of metastasis ($p=0.625$); however, VEGF levels tended to be higher in subjects with metastases (650.27pg/ml). There was a significant

Biography : *Rahmawati Minhajat* has completed his PhD at the age of 37 years from Saga University Japan and Consultant of Hematology and Medical Oncology from Internal Medicine Department Medical Faculty of Hasanuddin University Makassar Indonesia. She is a lecturer in Internal Medicine Department, Medical Faculty of Hasanuddin



Publication: Organ-specific endoglin (CD105) expression in the angiogenesis of human cancers
Methods of cancer diagnosis, therapy, and prognosis: liver cancer
The role of endothelial progenitor cell in cardiovascular disease risk factors
Tumor angiogenesis in cancers: expression of CD105 marker
Drugs Hypersensitivity Reaction in Patient with Human Immunodeficiency Virus (HIV) Infection

32nd International Conference on Cancer Research and Therapy, February 19-20, 2020

Abstract Citation : *Rahmawati Minhajat*, Profiles of Endoglin and Vascular Endothelial Growth Factor Based on Staging and Histological Grading of Colorectal Cancer, and Its Relationship with Bevacizumab Therapy Cancer, Osaka, Japan, February 19-20, 2020